Humanization of a mouse anti-human interleukin-6 receptor antibody comparing two methods for selecting human framework regions.

Mouse monoclonal antibody AUK12-20 binds to human IL-6 receptor and inhibits IL-6 functions. It has been humanized by CDR-grafting for therapeutic use. In the design of reshaped human AUK12-20 VL region, the human framework regions (FRs) from the human Bence-Jones protein REI were used. The reshaped human AUK12-20 light chain, in combination with chimeric AUK12-20 heavy chain, bound to antigen as well as chimeric AUK12-20 antibody. In the design of reshaped human AUK12-20 VH region, two sets of the human FRs were chosen and compared. One set was from the consensus amino acid sequence for human VH regions subgroup (HSG)-I and the other set was from human antibody HAX, the most similar human VH region found in a database of human immunoglobulin sequences. The HSG-I-based and the HAX-based reshaped human AUK12-20 heavy chains in combination with the reshaped human AUK12-20 light chain, showed approximately 90 and 100% antigen-binding and competition-binding activities as compared to the chimeric or mouse AUK12-20 heavy chains. Most importantly, these humanized antibodies inhibited the IL-6-dependent tumor cell growth as well as the original mouse antibody suggesting that these humanized antibodies could be efficacious in human patients. Our results show that both approaches for the design of reshaped human antibodies can be used for successful humanization. The approach based on FRs from the most similar individual human antibody, however, seemed to be best for designing a reshaped human antibody that mimicked as closely as possible the original mouse antibody.

[1]  H. Imura,et al.  Acquisition of growth autonomy and tumorigenicity by an interleukin 6-dependent human myeloma cell line transfected with interleukin 6 cDNA. , 1992, Experimental hematology.

[2]  R. Wheeler,et al.  Phase I trial of multiple large doses of murine monoclonal antibody CO17-1A. II. Pharmacokinetics and immune response. , 1988, Journal of the National Cancer Institute.

[3]  J. St,et al.  Rapid PCR-cloning of full-length mouse immunoglobulin variable regions. , 1991 .

[4]  A Tramontano,et al.  Framework residue 71 is a major determinant of the position and conformation of the second hypervariable region in the VH domains of immunoglobulins. , 1990, Journal of molecular biology.

[5]  A. Lesk,et al.  Conformations of immunoglobulin hypervariable regions , 1989, Nature.

[6]  H. Waldmann,et al.  Reshaping a therapeutic CD4 antibody. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[7]  P Davies,et al.  Optimal humanization of 1B4, an anti-CD18 murine monoclonal antibody, is achieved by correct choice of human V-region framework sequences. , 1993, Journal of immunology.

[8]  R. Sasaki,et al.  Expression of the erythropoietin receptor on a human myeloma cell line. , 1990, Biochemical and biophysical research communications.

[9]  T. Saito,et al.  Purification and characterization of soluble human IL-6 receptor expressed in CHO cells. , 1990, Journal of biochemistry.

[10]  G. Winter,et al.  Antibody framework residues affecting the conformation of the hypervariable loops. , 1992, Journal of molecular biology.

[11]  R. Schwartz,et al.  Relationship of human variable region heavy chain germ-line genes to genes encoding anti-DNA autoantibodies. , 1987, Journal of immunology.

[12]  J. Schlom,et al.  Pharmacokinetics and immune response of 131I-chimeric mouse/human B72.3 (human gamma 4) monoclonal antibody in humans. , 1991, Cancer research.

[13]  Lutz Riechmann,et al.  Reshaping human antibodies for therapy , 1988, Nature.

[14]  A. Hasegawa,et al.  Anti‐human interleukin‐6 receptor antibody inhibits human myeloma growth in vivo , 1992, European journal of immunology.

[15]  S. Matsushita,et al.  Construction of reshaped human antibodies with HIV-neutralizing activity. , 1991, Human antibodies and hybridomas.

[16]  J Saldanha,et al.  Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation. , 1991, Protein engineering.

[17]  E. Kabat,et al.  Sequences of proteins of immunological interest , 1991 .

[18]  J. Saldanha,et al.  Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. , 1993, Cancer Research.

[19]  N. Hilschmann,et al.  Die Primärstruktur einer monoklonalen Immunglobulin-L-Kette der Subgruppe IV vom κ-Typ (Bence-Jones-Protein Len.) , 1975 .

[20]  N. Hilschmann,et al.  Die Primärstruktur einer kristallinen monoklonalen Immunglobulin-L-Kette vom κ-Typ, Subgruppe I (Bence-Jones-Protein Rei.), Isolierung und Charakterisierung der tryptischen Peptide; die vollständige Aminosäuresequenz des Proteins. Ein Beitrag zur Aufklärung der räumlichen Struktur der Antikörper, in , 1975 .

[21]  A. Lesk,et al.  Canonical structures for the hypervariable regions of immunoglobulins. , 1987, Journal of molecular biology.

[22]  S. Shimizu,et al.  Establishment of two interleukin 6 (B cell stimulatory factor 2/interferon beta 2)-dependent human bone marrow-derived myeloma cell lines , 1989, The Journal of experimental medicine.

[23]  J. Ghrayeb,et al.  Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[24]  A. E. Ringwood,et al.  Terrestrial origin of the Moon , 1986, Nature.

[25]  T. Hirano,et al.  Characterization of IL-6 receptor expression by monoclonal and polyclonal antibodies. , 1989, Journal of immunology.

[26]  M. Matsuoka,et al.  An established CD4+ T lymphoma cell line derived from a patient with so-called Lennert's lymphoma: possible roles of cytokines in histopathogenesis. , 1988, Blood.

[27]  W. Grizzle,et al.  Phase I trial of the chimeric anti-GD2 monoclonal antibody ch14.18 in patients with malignant melanoma. , 1992, Human antibodies and hybridomas.

[28]  C. Milstein,et al.  Reshaping human antibodies: grafting an antilysozyme activity. , 1988, Science.